On the relevance of the drug Fuzailova “MP-anti-protein-blocker” with diagnostic and therapeutic purpose in the “IMEDIS-TEST” system
AUTHORS : Makina S.K. | Fuzailov B.N.
RELEVANT UNIVERSITIES : Petropavlovsk, Kazakhstan; Moscow, Russia
YEAR : 2008
For the first time at the VIII International Conference “Theoretical and Clinical Aspects of the Application of Bioresonance and Multiresonance Therapy” Fuzailov B.N. and Shraibman MM reported on the use of the anti-cancer drug Fuzailova (PF) “MP-anti-protein-blocker” for diagnostic and therapeutic purposes in cancer patients. Patent for invention No. 2293564 (method for diagnosing
and treating malignant tumors) was registered by the authors in the state register of inventions of the Russian Federation on February 20, 2007. Center “IMEDIS” (Moscow) in the medication selector Fuzailov’s potentiated drug No. 1, 2, 3, 4, 5 in the section “Oncodiagnostics”. In the same section of the research by M.M. and Rapis E.G. were taken as the basis for the tests “oncoprotein” and “normal
protein”, which are informational copies of photographs of the structures of a healthy